Key Points Johnson & Johnson has raised its dividend for 64 straight years, but faces billions in talc-related litigation liabilities. Kenvue offers a higher yield of 4.71%, but its pending acquisition by Kimberly-Clark creates uncertainty about its dividend outlook. Analysts rate J&J a "Moderate Buy," while Kenvue has a "Hold" rating amid its unresolved merger. 10 stocks we like better than Johnson & Johnson › Dividend investors looking for a defensive healthcare candidate will likely come across companies like Johnson & Johnson (NYSE: JNJ) and Kenvue (NYSE: KVUE) , and the next natural question is which one deserves a permanent spot in a dividend portfolio.
Publicznie pokazujemy glowna mysl. Utworz darmowe konto, aby czytac caly artykul, zapisac go, omowic i polaczyc z kontekstem rynkowym oraz OSINT.